Clinical trials recruiting for Head and Neck Squamous Cell Carcinoma

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
  NCT06022029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
  NCT06700070 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
  NCT07462377 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
  NCT06150664 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
  NCT05902988 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
  NCT03526835 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  NCT07503808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• A Study of IDP-001 in Advanced or Metastatic Solid Tumors
  NCT07602842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
  NCT07274852 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
  NCT05859074 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
  NCT05877599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Study of VET3-TGI in Patients With Solid Tumors
  NCT06444815 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
  NCT06747585 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
  NCT07115043 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
  NCT06422403 · Phase: Phase 2 · Ages: 21 Years to 99 Years · Sex: All (male and female) · 1 location
• Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
  NCT03740256 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
  NCT06575322 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 117 locations
• FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
  NCT07216105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• First in Human Study of SIM0610 in Solid Tumors
  NCT07348211 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients
  NCT07511413 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
  NCT05913388 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients
  NCT07514754 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• HRYZ-T101 Injection for HPV18 Positive Solid Tumor
  NCT05952947 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
  NCT05229614 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• PET-imaging of Two Vartumabs in Patients With Solid Tumors
  NCT06645808 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
  NCT07589205 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
  NCT04429542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
  NCT05784688 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
  NCT06084481 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
  NCT05005403 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
  NCT04969315 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
  NCT06451497 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
  NCT03556228 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 15 locations

Related conditions

Trials recruiting for Head and Neck Squamous Cell Carcinoma often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Head and Neck Squamous Cell Carcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.